Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on DP POLAND PLC. We currently have 4 research reports from 3 professional analysts.
|14Feb17 07:00||RNS||Holding(s) in Company|
|10Feb17 14:23||RNS||Holding(s) in Company|
|08Feb17 07:00||RNS||Update on store performance|
|22Dec16 07:00||RNS||Issue of Equity|
|02Dec16 13:16||RNS||Director/PDMR Shareholding|
|01Dec16 07:00||RNS||Sale and sub-franchising of Krakow stores|
|14Oct16 16:12||RNS||Director/PDMR Shareholding|
Frequency of research reports
Research reports on
DP POLAND PLC
DP POLAND PLC
Small Cap Breakfast
08 Feb 17
Arix Bioscience — Intention to float on the main market from the global healthcare and life science Company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management Ramsdens Holdings –Schedule One from the financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second hand and new jewellery. Expected admission to AIM 15 Feb raising circa £15.6m. Expected mkt cap £26.5m.
DP Poland overview
04 Nov 16
DP Poland, through its wholly owned subsidiary DP Polska S.A., has the exclusive right to develop, operate and sub-franchise Domino’s Pizza stores in Poland. At the time of the release of the company’s Interim results on 19 September 2016 there were 29 Domino’s Pizza stores in 7 Polish cities, 16 corporately managed and 13 sub-franchised. The company’s 2016 Interim results showed a 15th consecutive quarter of double-digit like-for-like growth, with H1 16 total Group revenue up 70% year on year. Corporate store EBITDA continues to grow, as does the Commissary gross pro t, however Group EBITDA remains negative as management continues to invest in the business to support the store roll-out plan.
05 Oct 16
ACE LIBERTY & STONE PLC (ALSP PZ) | DP POLAND PLC (DPP LN) | FUSIONEX INTERNATIONAL PLC (FXI LN) | GOOCH & HOUSEGO PLC (GHH LN) | KODAL MINERALS PLC (KOD LN) | OPTIBIOTIX HEALTH PLC (OPTI LN) | PARK GROUP (PKG LN) | PREMIER AFRICAN MINERALS LTD (PREM LN) | SAFECHARGE INTL GROUP LTD (SCH LN) | TIME OUT GROUP PLC (TMO LN)
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
Acceptance of all-cash offer by Kindred Group
23 Feb 17
32Red has agreed an all cash takeover by Kindred, at 196p per share. Together with an approved 4p dividend, this represents a 32.4% premium to last month’s average. This equates to 10.6x EV/EBITDA and 14.3x P/E for 2017, a small premium to the larger peer group. Given 32Red’s brand strength, regulated bias and growth momentum, this appears justified.
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
N+1 Singer - CVS Group - Strong AGM prompts double-digit upgrades
24 Nov 16
CVS has issued a strong AGM statement which further justifies its premium rating. For the first 4 months to October it has traded “ahead of the Board’s expectations”, registering an impressive 6.3% LFL showing. It has also been busy consolidating and established a foothold in the Dutch market. We push through 10% EPS upgrades for each of the next 3 years and see further upside risk. The strength of the update shows CVS continues to have strong momentum and we argue for fair value towards 1100p.
N+1 Singer - Gym Group - Not quite a lean, fit & healthy outlook
15 Feb 17
Gym Group has done an excellent job in successfully rolling out a disruptive business model in the health & fitness market. However, we think growth expectations are too high and the shares look expensive on a FY17 P/E of 27x. We expect initial signs of increased competition / cannibalisation and LFL pressure to increase over the next 2-3 years and the shares to de-rate. We pitch our forecasts 5%-14% below consensus and initiate with a Sell recommendation and a 145p target price.